Cargando…
The quality of afterlife: surviving extracorporeal life support after therapy‐refractory circulatory failure—a comprehensive follow‐up analysis
AIMS: Extracorporeal life support (ECLS) represents a popular treatment option for therapy‐refractory circulatory failure and substantially increases survival. However, comprehensive follow‐up (FU) data beyond short‐term survival are mostly lacking. Here, we analyse functional recovery and quality o...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712909/ https://www.ncbi.nlm.nih.gov/pubmed/34480427 http://dx.doi.org/10.1002/ehf2.13554 |
_version_ | 1784623661823557632 |
---|---|
author | Immohr, Moritz Benjamin Eschlböck, Sophie Margaretha Rellecke, Philipp Dalyanoglu, Hannan Tudorache, Igor Boeken, Udo Akhyari, Payam Albert, Alexander Lichtenberg, Artur Aubin, Hug |
author_facet | Immohr, Moritz Benjamin Eschlböck, Sophie Margaretha Rellecke, Philipp Dalyanoglu, Hannan Tudorache, Igor Boeken, Udo Akhyari, Payam Albert, Alexander Lichtenberg, Artur Aubin, Hug |
author_sort | Immohr, Moritz Benjamin |
collection | PubMed |
description | AIMS: Extracorporeal life support (ECLS) represents a popular treatment option for therapy‐refractory circulatory failure and substantially increases survival. However, comprehensive follow‐up (FU) data beyond short‐term survival are mostly lacking. Here, we analyse functional recovery and quality of life of longer‐term survivors. METHODS AND RESULTS: Between 2011 and 2016, a total of n = 246 consecutive patients were treated with ECLS for therapy‐refractory circulatory failure in our centre. Out of those, 99 patients (40.2%) survived the first 30 days and were retrospectively analysed. Fifty‐eight patients (23.6%) were still alive after a mean FU of 32.4 ± 16.8 months. All surviving patients were invited to a prospective, comprehensive clinical FU assessment, which was completed by 39 patients (67.2% of survivors). Despite high incidence of early functional impairments, FU assessment revealed a high degree of organ and functional recovery with more than 70% of patients presenting with New York Heart Association class ≤ II, 100% free of haemodialysis, 100% free of moderate or severe neurological disability, 71.8% free of moderate or severe depression, and 84.4% of patients reporting to be caring for themselves without need for assistance. CONCLUSIONS: Patients surviving the first 30 days of ECLS therapy for circulatory failure without severe adverse events have a quite favourable outcome in terms of subsequent survival as well as functional recovery, showing the potential of ECLS therapy for patients to recover. Patients can recover even after long periods of mechanically support and regain physical and mental health to participate in their former daily life and work. |
format | Online Article Text |
id | pubmed-8712909 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87129092022-01-04 The quality of afterlife: surviving extracorporeal life support after therapy‐refractory circulatory failure—a comprehensive follow‐up analysis Immohr, Moritz Benjamin Eschlböck, Sophie Margaretha Rellecke, Philipp Dalyanoglu, Hannan Tudorache, Igor Boeken, Udo Akhyari, Payam Albert, Alexander Lichtenberg, Artur Aubin, Hug ESC Heart Fail Original Articles AIMS: Extracorporeal life support (ECLS) represents a popular treatment option for therapy‐refractory circulatory failure and substantially increases survival. However, comprehensive follow‐up (FU) data beyond short‐term survival are mostly lacking. Here, we analyse functional recovery and quality of life of longer‐term survivors. METHODS AND RESULTS: Between 2011 and 2016, a total of n = 246 consecutive patients were treated with ECLS for therapy‐refractory circulatory failure in our centre. Out of those, 99 patients (40.2%) survived the first 30 days and were retrospectively analysed. Fifty‐eight patients (23.6%) were still alive after a mean FU of 32.4 ± 16.8 months. All surviving patients were invited to a prospective, comprehensive clinical FU assessment, which was completed by 39 patients (67.2% of survivors). Despite high incidence of early functional impairments, FU assessment revealed a high degree of organ and functional recovery with more than 70% of patients presenting with New York Heart Association class ≤ II, 100% free of haemodialysis, 100% free of moderate or severe neurological disability, 71.8% free of moderate or severe depression, and 84.4% of patients reporting to be caring for themselves without need for assistance. CONCLUSIONS: Patients surviving the first 30 days of ECLS therapy for circulatory failure without severe adverse events have a quite favourable outcome in terms of subsequent survival as well as functional recovery, showing the potential of ECLS therapy for patients to recover. Patients can recover even after long periods of mechanically support and regain physical and mental health to participate in their former daily life and work. John Wiley and Sons Inc. 2021-09-04 /pmc/articles/PMC8712909/ /pubmed/34480427 http://dx.doi.org/10.1002/ehf2.13554 Text en © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Immohr, Moritz Benjamin Eschlböck, Sophie Margaretha Rellecke, Philipp Dalyanoglu, Hannan Tudorache, Igor Boeken, Udo Akhyari, Payam Albert, Alexander Lichtenberg, Artur Aubin, Hug The quality of afterlife: surviving extracorporeal life support after therapy‐refractory circulatory failure—a comprehensive follow‐up analysis |
title | The quality of afterlife: surviving extracorporeal life support after therapy‐refractory circulatory failure—a comprehensive follow‐up analysis |
title_full | The quality of afterlife: surviving extracorporeal life support after therapy‐refractory circulatory failure—a comprehensive follow‐up analysis |
title_fullStr | The quality of afterlife: surviving extracorporeal life support after therapy‐refractory circulatory failure—a comprehensive follow‐up analysis |
title_full_unstemmed | The quality of afterlife: surviving extracorporeal life support after therapy‐refractory circulatory failure—a comprehensive follow‐up analysis |
title_short | The quality of afterlife: surviving extracorporeal life support after therapy‐refractory circulatory failure—a comprehensive follow‐up analysis |
title_sort | quality of afterlife: surviving extracorporeal life support after therapy‐refractory circulatory failure—a comprehensive follow‐up analysis |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712909/ https://www.ncbi.nlm.nih.gov/pubmed/34480427 http://dx.doi.org/10.1002/ehf2.13554 |
work_keys_str_mv | AT immohrmoritzbenjamin thequalityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis AT eschlbocksophiemargaretha thequalityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis AT relleckephilipp thequalityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis AT dalyanogluhannan thequalityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis AT tudoracheigor thequalityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis AT boekenudo thequalityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis AT akhyaripayam thequalityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis AT albertalexander thequalityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis AT lichtenbergartur thequalityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis AT aubinhug thequalityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis AT immohrmoritzbenjamin qualityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis AT eschlbocksophiemargaretha qualityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis AT relleckephilipp qualityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis AT dalyanogluhannan qualityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis AT tudoracheigor qualityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis AT boekenudo qualityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis AT akhyaripayam qualityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis AT albertalexander qualityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis AT lichtenbergartur qualityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis AT aubinhug qualityofafterlifesurvivingextracorporeallifesupportaftertherapyrefractorycirculatoryfailureacomprehensivefollowupanalysis |